EMA calls for As­traZeneca vac­ci­na­tions to con­tin­ue af­ter safe­ty scares de­layed roll­out

The Eu­ro­pean Med­i­cines Agency (EMA) said Thurs­day that the use of As­traZeneca’s vac­cine should con­tin­ue as new de­tails emerge of some of the cas­es that led more than 20 Eu­ro­pean coun­tries to halt their use of the As­traZeneca vac­cine.

The EMA’s Phar­ma­covig­i­lance Risk As­sess­ment Com­mit­tee (PRAC) “has come to a clear sci­en­tif­ic con­clu­sion that this is a safe and ef­fec­tive vac­cine,” EMA ex­ec­u­tive di­rec­tor Emer Cooke said in a press con­fer­ence. The com­mit­tee rec­om­mend­ed rais­ing aware­ness of these pos­si­ble rare con­di­tions to help spot and mit­i­gate any pos­si­ble side ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER